title: Malignant intertrigo: A subset of toxic erythema of chemotherapy requiring recognition.
authors.affiliation: Department of Internal Medicine, Division of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio.
authors.forename: Sabrina M
authors.initials: SM
authors.lastname: Smith
authors.affiliation: Department of Internal Medicine, Division of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio.
authors.forename: Philip B
authors.initials: PB
authors.lastname: Milam
authors.affiliation: Department of Internal Medicine, Division of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio.
authors.forename: Stephanie K
authors.initials: SK
authors.lastname: Fabbro
authors.affiliation: Department of Pathology, University of Virginia, Charlottesville, Virginia.
authors.forename: Alejandro A
authors.initials: AA
authors.lastname: Gru
authors.affiliation: Department of Internal Medicine, Division of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio.
authors.forename: Benjamin H
authors.initials: BH
authors.lastname: Kaffenberger
keywords: MI, malignant intertrigo; PPE, palmoplantar erythrodysesthesia; SDRIFE, symmetrical drug-related intertriginous, flexural exanthema; TEC, toxic erythema of chemotherapy; chemotherapy; drug eruption; graft-versus-host disease; intertrigo; pathogenesis; toxic erythema of chemotherapy